Skip to main
CRMD

CorMedix (CRMD) Stock Forecast & Price Target

CorMedix (CRMD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cormedix Inc. has demonstrated a strong financial performance by raising its full-year 2025 pro forma net revenue guidance to $390–$410 million, surpassing its previous estimate of at least $375 million, driven by increased adoption of DefenCath and contributions from the Melinta portfolio. The company also anticipates fourth-quarter net revenue between $115 million and $135 million, indicating robust momentum heading into the year-end. Additionally, the projected fully synergized pro forma adjusted EBITDA range of $220–$240 million further reinforces the positive outlook for Cormedix's financial health and growth trajectory.

Bears say

Cormedix is facing significant uncertainty due to the TDAPA pricing headwind, which could negatively impact its revenue potential and gross margin from its product, DefenCath. While there is a recognition of a potential $100 million to $200 million market opportunity with Niyadas, the reliance on strategic commercial infrastructure in a single market, the United States, poses a risk to sustained profitability. Overall, despite some anticipated tailwinds, the financial outlook remains encumbered by pricing uncertainties that could adversely affect EBITDA margins in the near term.

CorMedix (CRMD) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CorMedix and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CorMedix (CRMD) Forecast

Analysts have given CorMedix (CRMD) a Buy based on their latest research and market trends.

According to 6 analysts, CorMedix (CRMD) has a Buy consensus rating as of Dec 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $18.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $18.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CorMedix (CRMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.